News and Events – COD Research

WDSC-Web-Upcoming

7 months ago

WDSC upcoming

Posted by cppl_codresearch_2022

Bio-2024-Attendee-Web-01_ Upcoming

Bio 2024 upcoming

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

DIA 2023 in Boston, Massachusetts

CODE Exhibiting at BIO 2024

DCAT 2023 in New York City

Scope 2023 in Orlando, Florida

Events

2 years ago

Pharmacovigilance System guideline of South Africa – A high level glance

Events

2 years ago

COD research is delighted to present on “Career Opportunities in Pharmacovigilance”

Events

2 years ago

An insightful session on “ISO: 14155- Introduction to Clinical Investigation for Medical Devices” by Dr. Ashok Thakkar

Events

2 years ago

38th International Society for Pharmacoepidemiology (ICPE)

Events

2 years ago

We are delighted to welcome Mohit Kapoor as Director – Project Management and Operations Strategy

Events

2 years ago

We are the silver sponsor at WDSC-2022

Events

2 years ago

Dr Jay Dave is among the selected speakers to give a presentation during the event.

Events

2 years ago

Experts at our Booth # 42 are awaiting your presence to unlock your Drug Safety Challenges and enhance compliance.

Events

2 years ago

CPhI Frankfurt is calling!

Events

2 years ago

COD Research USA INC is attending World Drug Safety Congress – 2022, Boston.

Draft qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology in liver biopsies to determine disease activity in NASH/MASH clinical trials
Source: EMA Published on 2024-12-06
Q&A Clinic on post-authorisation procedure management in IRIS (1), Online, from 11 December 2024, 11:00 (CET) to 11 December 2024, 12:00 (CET)
Source: EMA Published on 2024-12-06
2024 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA), Online, European Medicines Agency, Amsterdam, the Netherlands, 1 October 2024
Source: EMA Published on 2024-12-05
Ibandronic acid Accord
Source: EMA Published on 2024-12-05
Human medicines European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD), alendronic acid,colecalciferol, Date of authorisation: 16/10/2009, Revision: 21, Status: Authorised
Source: EMA Published on 2024-12-05
Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline
Source: EMA Published on 2024-12-05
Guidance for applicants seeking scientific support and advice on traditional herbal medicinal products
Source: EMA Published on 2024-12-05
Human medicines European public assessment report (EPAR): Arsenic trioxide Accord, arsenic trioxide, Date of authorisation: 14/11/2019, Revision: 7, Status: Authorised
Source: EMA Published on 2024-12-05
Three-year work plan for the Quality Drafting Group (QDG) of the Committee on Herbal Medicinal Products (HMPC)
Source: EMA Published on 2024-12-05
Data protection notice for the Experts Management Tool and the handling of competing interests
Source: EMA Published on 2024-12-05
Human medicines European public assessment report (EPAR): Jcovden (previously COVID-19 Vaccine Janssen), COVID-19 vaccine (Ad26.COV2-S [recombinant]), Date of authorisation: 11/03/2021, Revision: 33, Status: Withdrawn (authorisation)
Source: EMA Published on 2024-12-05
Jcovden : Periodic safety update report assessment 25 February 2023 to 24 February 2024
Source: EMA Published on 2024-12-05
Human medicines European public assessment report (EPAR): Duloxetine Viatris (previously Duloxetine Mylan), duloxetine, Date of authorisation: 19/06/2015, Revision: 20, Status: Authorised
Source: EMA Published on 2024-12-04
How to pay
Source: EMA Published on 2024-12-04
How to pay fees and charges levied by EMA: Guidance to marketing authorisation holders and applicants
Source: EMA Published on 2024-12-04

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Field Safety Notices: 25 to 29 November 2024
Source: MHRA Published on 2024-12-05
Class 4 Medicines Defect Information: Brillpharma Limited, Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution, EL(24)A/61
Source: MHRA Published on 2024-12-04
Class 4 Medicines Defect Information: Kent Pharma UK, Phenoxymethylpenicillin 250mg/5ml Oral Solution Sugar Free, EL (24)A/60
Source: MHRA Published on 2024-12-03
Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension, EL(24)A/59
Source: MHRA Published on 2024-12-02
Class 4 Medicines Defect Information: Strides Pharma UK Ltd, Liothyronine Sodium 5 & 20 micrograms Tablets, EL(24)A/58
Source: MHRA Published on 2024-11-28
Class 4 Medicines Defect Information: Morningside Healthcare Limited, Tramadol Hydrochloride 50 mg capsules & Tramadol Hydrochloride Morningside 50 mg Prolonged-Release capsules, EL(24)A/57
Source: MHRA Published on 2024-11-27
Field Safety Notices: 18 to 22 November 2024
Source: MHRA Published on 2024-11-26
Field Safety Notices: 25 November 2024
Source: MHRA Published on 2024-11-26
Class 3 Medicines Recall: Syri Limited, T/A SyriMed, Baclofen 10mg/5ml Oral Solution, EL(24)A/56
Source: MHRA Published on 2024-11-25
Field Safety Notices: 11 to 15 November 2024
Source: MHRA Published on 2024-11-19
Class 4 Medicines Defect Information: Takeda UK Limited, Entyvio 108mg solution for injection in pre-filled syringe, EL(24)A/55
Source: MHRA Published on 2024-11-18
Company led medicines recall: Leeds Trading Company LTC Ltd T/A LTC Healthcare, EXS Delay Spray Plus, CLMR(24)A/01
Source: MHRA Published on 2024-11-13
Class 4 Medicines Defect Information: Viatris UK Healthcare Ltd, Omeprazole 40 mg Powder for solution for infusion, EL(24)A/54
Source: MHRA Published on 2024-11-12
Field Safety Notices: 4 to 8 November 2024
Source: MHRA Published on 2024-11-12
Field Safety Notices: 8 November 2024
Source: MHRA Published on 2024-11-08

FDA

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Biosimilar-main-slider

Upcoming Events

News &
Events

Explore

Drag